Antiretroviral therapy for previously treated patients

New England Journal of Medicine

Volumn 345, Issue 6, 2001, Pages 452-455

  Montaner, Julio S G ^a   Mellors, John W ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; EFAVIRENZ; ENFUVIRTIDE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MIXTURE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION; VIRUS RESISTANCE;

DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NELFINAVIR; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE;

EID: 0035833384     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200108093450610     Document Type: Editorial

References (23)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
3. AIDS across Europe, 1994-98: The EuroSIDA study
4. AIDS - Will the next 20 years be different?
5. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
6. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359
7. sgc, indinavir or nelfinavir in combination with amprenavir, abacavir, efavirenz, and adefovir in patients with protease inhibitor failure
8. HIV-1 drug resistance in newly infected individuals
9. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
10. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
11. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
12. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) 1250 mg bid in treatment-naive patients improves therapeutic outcome after one year: Results from ATHENA
13. Response to ritonavir intensification in indinavir recipients is highly correlated with virtual inhibitory quotient
14. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
15. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival
16. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection
17. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
18. Clinical HIV suppression after short-term monotherapy with DAPD
19. Tenofovir disoproxil fumarate (TDF) for the treatment of antiviral experienced patients: A double-blind, placebo-controlled study
20. Safety and efficacy of tipranavir, a non-peptidic protease inhibitor, in multiple PI-failure patients
21. A controlled phase II trial assessing three doses of T20 in combination with abacavir, amprenavir, low-dose ritonavir and efavirenz in non-nucleoside naive protease inhibitor experienced HIV-1 infected adults
22. A 14-day assessment of the safety, pharmacokinetics, and antiviral activity of T1249, a peptide inhibtor of membrane fusion